Mometasone Furoate and Formoterol Fumarate Inhalation Aerosol (Dulera)

Elliott, William T.; Chan, James
September 2010
Internal Medicine Alert;9/1/2010, Vol. 32 Issue 18, p142
The article offers information on the indications, recommended dosage and clinical implications of mometasone furoate (MF) and formoterol.


Related Articles

  • Spinosad Topical Suspension 0.9% (Natroba). Elliott, William T.; Chan, James // Internal Medicine Alert;2/28/2011, Vol. 33 Issue 4, p30 

    The article offers information on the indication, dosage, and effectiveness of Spinosad Topical Suspension 0.9%, a topical treatment for head lice infestation.

  • Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. Brüggenjürgen, Bernd; Selim, Dagmar; Kardos, Peter; Richter, Kai; Vogelmeier, Claus; Roll, Stephanie; Meyer-Sabellek, Wolfgang; Buhl, Roland; Willich, Stefan N.; Brüggenjürgen, Bernd // PharmacoEconomics;2005, Vol. 23 Issue 7, p723 

    Objectives: To compare the costs and effectiveness of adjustable maintenance dosing with budesonide/formoterol in a single inhaler versus fixed dosing in adults with asthma. Methods: In this prospective, randomised, open-label, parallel-group, multicentre trial conducted in Germany, patients...

  • Spectrophotometric estimation of purlifloxacin in bulk and pharmaceutical dosage form by UV spectrophotometry. Dey, Suddhasattya; Samal, Himansu Bhusan; Kumar, Dhiraj; Vaidanathanan, S.; Ratnakar, C. H.; Mohapatra, Subhasis; Patnaik, Ansuman; Kumar, D. Bharat // Drug Invention Today;Oct2010, Vol. 2 Issue 10, p454 

    The present study describes a simple, accurate, precise and cost effective UV-VIS Spectrophotometric method for the estimation of PURLIFLOXACIN, a fluroquinolone derivative, in bulk and pharmaceutical dosage form. The solvent used was 0.1NNaoH and thelmax or the absorption maxima of the drug was...

  • ENTRY FORMAT.  // Monthly Prescribing Reference;Jul2011, Vol. 27 Issue 7, pA.6 

    A chapter of the book "Monthly Prescribing Reference" is presented. It presents the format for the submission of entry for monograph on drug at "Monthly Prescribing Reference." It requires the entry to include the main name under which the product and all other dosage forms in the monograph are...

  • Current FDA-Related Drug Information. Baker, Danial E. // Hospital Pharmacy;Jan2007, Vol. 42 Issue 1, p74 

    Several tables are presented that provide information on new drugs approved by the U.S. Food and Drug Administration (FDA), new dosage forms and indications, agents with pending FDA approval and labeling changes related to drug safety.

  • A Rapid, Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Formoterol Fumarate, Tiotropium Bromide, and Ciclesonide in a Pulmonary Drug Product. Trivedi, Rakshit Kanubhai; Chendake, Dhairyshil S.; Patel, Mukesh C. // Scientia Pharmaceutica;2012, Vol. 80 Issue 3, p591 

    A stability-indicating reversed-phase high performance liquid chromatography (RP-HPLC) method was developed for the simultaneous determination of Formoterol fumarate (FOR), Tiotropium bromide (TRI), and Ciclesonide (CLS) in a pulmonary drug product. The desired chromatographic separation was...

  • TYPICAL ENTRY.  // Monthly Prescribing Reference;May2012, Vol. 28 Issue 5, pA-23 

    The article offers key labeling information of the prescribed products and formulations that has been illustrated with a labeling of a diuretic drug named as Demadex from F. Hoffmann-La Roche Ltd. The labeling include brand name of a drug, name of the company manufacturing a drug, and...

  • Veterinary medicines: product update.  // Veterinary Record: Journal of the British Veterinary Association;9/12/2015, Vol. 177 Issue 10, p250 

    The article offers a look at changes made by the British Veterinary Medicines Directorate (VMD) to marketing authorisations for veterinary medicines and products as of July 2015. Particular focus is given to the new active ingredients of Ectoline and Fipralone for flea control in dogs. Also...

  • MHRA to review the safety and use of LABAs.  // GP: General Practitioner;3/2/2007, p4 

    The article reports that the Medicines and Healthcare Products Regulatory Agency (MHRA) of Great Britain is reviewing the use of the long-acting beta-2 agonists (LABAs) formoterol and salmeterol in the treatment of asthma and COPD patients. Understanding how corticosteroid inhalers can influence...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics